Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Everest Medicines Limited commences an Equity Buyback Plan for 29,684,786 shares, representing 10% of its issued share capital, under the authorization approved on June 1, 2021.

10/04/2021 | 08:10am EST

Everest Medicines Limited (SEHK:1952) commences share repurchases on October 4, 2021, under the program mandated by the shareholders in the Annual General Meeting held on June 1, 2021. As per the mandate, the company is authorized to repurchase up to 29,684,786 shares, representing 10% of its issued share capital. The purpose of this repurchase program is to enhance the earnings per share of the company. The repurchases will be funded entirely from the company’s available cash flow or working capital facilities which will be funds legally available for the purpose in accordance with the bye-laws and the laws of the jurisdiction in which the company is incorporated. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 1, 2021, the company had 296,847,861 shares in issue.


ę S&P Capital IQ 2021
All news about EVEREST MEDICINES LIMITED
11/23Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China..
PR
11/10Everest Medicines' Phase 2b Trial in China of Breast Cancer Drug Meets Study Endpoint; ..
MT
11/08Everest Medicines Eyes Buyback of Nearly $13 Million Worth of Shares
MT
11/07Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
PR
10/31Everest Medicines Announces Share Repurchase Transaction Details
PR
10/09Certain Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending o..
CI
10/04Everest Medicines Limited commences an Equity Buyback Plan for 29,684,786 shares, repre..
CI
09/30EVEREST MEDICINES' : New Drug Application for Complicated Intra-Abdominal Infections Treat..
MT
09/29Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaT..
CI
09/29EVEREST MEDICINES : Initiates Submission of New Drug Application in Hong Kong for XeravaTM..
PR
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Financials
Sales 2021 1,92 M 0,30 M 0,30 M
Net income 2021 -1 046 M -164 M -164 M
Net cash 2021 3 029 M 474 M 474 M
P/E ratio 2021 -10,7x
Yield 2021 -
Capitalization 11 349 M 1 455 M 1 777 M
EV / Sales 2021 4 341x
EV / Sales 2022 12,2x
Nbr of Employees 227
Free-Float 100%
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 38,25 CNY
Average target price 85,27 CNY
Spread / Average Target 123%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Chairman
Jennifer Yang Chief Scientific Officer
Xiaofan Zhang Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED-43.50%1 508
CSL LIMITED8.41%101 196
WUXI BIOLOGICS (CAYMAN) INC.3.50%56 285
SAMSUNG BIOLOGICS CO.,LTD.7.02%48 100
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.80%35 680